Glenmark Pharmaceuticals Expands U.S. Generic Injectable Portfolio with Methylene Blue Injection Launch

Glenmark Pharmaceuticals has revealed approval of Methylene Blue Injection USP (50 mg/10 mL [5 mg/mL]) for launch in the United States as part of its expanded portfolio of generic injectable (GI) products and to support its institutional/hospital-based therapeutic strategy. The launch reflects Glenmark's focus on impacting niche therapeutic unmet needs in the U.S. healthcare system and applicability in highly complex generics and injectables.

Expanding Presence in U.S. Generic Injectables

The launch of Methylene Blue Injection is part of Glenmark's robust strategy of generics business growth in the United States, which involves scaling up its generic injection business, complex generics, and authorized generics programs. It has also announced other plans to diversify its launch strategy, such as Milnacipran tablets, Sodium Phosphates Injection, and an oncology drug called Eribulin, among others.

Glenmark has also been reported to have a major presence in the U.S., having 215+ authorized generic products, a 14th-grade position in the generics business in the U.S., with annual prescriptions exceeding 90 million, and a pipeline of 110+ approved ANDAs and another 135 products are under application or development.

According to Precedence Research, the Generic Injectable Market size was calculated at USD 133.34 billion in 2025 and is predicted to increase from USD 152.01 billion in 2026 to approximately USD 482.50 billion by 2035, expanding at a CAGR of 13.72% from 2026 to 2035 as healthcare systems adopt the cost-effective, hospital-based, quality injectable treatments.

Industry Impact and Outlook

The U.S. pharmaceutical market is making strategic moves towards niche generics injectables currently, with June, 2026, with June's Glenmark launch of Methylene Blue Injection on the horizon, which can be viewed as a significant change in health care dynamics across the country. The company is still developing innovative portfolio segments, in hospital injectables, specialty products, and value-added generic products.  

This is representative of conditions in the wider market, where the marketing of generic manufacturers' products is more appropriate for targeted, institutional, and injectable products, where it is being spurred on by price pressures as opposed to value.